Dicks Sporting Goods Inc vs Summit Therapeutics Inc — how do they compare? Dicks Sporting Goods Inc trades at $203 (market cap $18.35B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Dicks Sporting Goods Inc is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| DKS | SMMT | |
|---|---|---|
Market Cap | $18.35B | $12.06B |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $26.98 |
52-Week Low | $187.78 | $12.55 |
Enterprise Value | $25.14B | $11.39B |
Dividend Yield | 2.44% | — |
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $202.66, down 5.34% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a 4.71% net income margin and 20.9% ROE, while analyst consensus remains strongly bullish with a $263.22 price target. Recent news highlights DKS as a value stock pick with accelerating sales growth, though the stock faces near-term technical pressure.
The outlook remains positive given strong analyst support and consistent earnings performance, but investors should monitor the bearish technical indicators and upcoming Q2 2026 earnings report on August 25th. Key risks include retail sector competition and potential margin pressure as revenue growth outpaces profit growth in 2026 projections.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Trailing returns across standard periods
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →